Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1975 7
1976 12
1977 18
1978 27
1979 48
1980 88
1981 58
1982 68
1983 91
1984 103
1985 133
1986 132
1987 142
1988 147
1989 173
1990 196
1991 161
1992 212
1993 217
1994 253
1995 217
1996 257
1997 276
1998 305
1999 286
2000 339
2001 344
2002 344
2003 437
2004 464
2005 526
2006 644
2007 683
2008 795
2009 801
2010 994
2011 1063
2012 1173
2013 1247
2014 1253
2015 1292
2016 1293
2017 1316
2018 1385
2019 1339
2020 1383
2021 1303
2022 1157
2023 1036
2024 906

Text availability

Article attribute

Article type

Publication date

Search Results

24,439 results

Results by year

Filters applied: . Clear all
Page 1
Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
Brufsky AM, Dickler MN. Brufsky AM, et al. Oncologist. 2018 May;23(5):528-539. doi: 10.1634/theoncologist.2017-0423. Epub 2018 Jan 19. Oncologist. 2018. PMID: 29352052 Free PMC article. Review.
The estrogen receptor-alpha is a predominant endocrine regulatory protein in the breast and in estrogen-induced BC. ...IMPLICATIONS FOR PRACTICE: The foundational strategy for treating hormone receptor-positive, human epidermal growth …
The estrogen receptor-alpha is a predominant endocrine regulatory protein in the breast and in estrogen-induced …
A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer.
Clusan L, Ferrière F, Flouriot G, Pakdel F. Clusan L, et al. Int J Mol Sci. 2023 Apr 6;24(7):6834. doi: 10.3390/ijms24076834. Int J Mol Sci. 2023. PMID: 37047814 Free PMC article. Review.
Breast cancer is the most common cancer and the deadliest among women worldwide. Estrogen signaling is closely associated with hormone-dependent breast cancer (estrogen and progesterone receptor positive), which accou …
Breast cancer is the most common cancer and the deadliest among women worldwide. Estrogen signaling is closely a …
Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy.
Schlefman J, Brenin C, Millard T, Dillon P. Schlefman J, et al. Med Oncol. 2023 Dec 16;41(1):19. doi: 10.1007/s12032-023-02255-8. Med Oncol. 2023. PMID: 38103078 Review.
The treatment landscape of hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer has evolved dramatically in recent years. ...The abundance of therapeutic options not only delay time to cytotoxic c …
The treatment landscape of hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic b …
Estrogen and progesterone receptors in breast cancer.
Yip CH, Rhodes A. Yip CH, et al. Future Oncol. 2014 Nov;10(14):2293-301. doi: 10.2217/fon.14.110. Future Oncol. 2014. PMID: 25471040 Review.
Breast cancer is the most common cancer in women worldwide. The majority of breast cancers show overexpression of estrogen receptors (ERs) and progesterone receptors (PRs). The development of drugs to target these hormone recept …
Breast cancer is the most common cancer in women worldwide. The majority of breast cancers show overexpression o …
Managing a Long and Winding Road: Estrogen Receptor-Positive Breast Cancer.
Gnant M, Turner NC, Hernando C. Gnant M, et al. Am Soc Clin Oncol Educ Book. 2023 Jun;43:e390922. doi: 10.1200/EDBK_390922. Am Soc Clin Oncol Educ Book. 2023. PMID: 37319380 Free article. Review.
We review key topics in the management of estrogen receptor (ER)-positive human epidermal growth factor receptor 2-negative breast cancer. ...CDK4/6 inhibitors have become a standard treatment option for high-risk patients in both the adj …
We review key topics in the management of estrogen receptor (ER)-positive human epidermal growth factor receptor …
Nanomedicine in therapeutic warfront against estrogen receptor-positive breast cancer.
Aalhate M, Mahajan S, Singh H, Guru SK, Singh PK. Aalhate M, et al. Drug Deliv Transl Res. 2023 Jun;13(6):1621-1653. doi: 10.1007/s13346-023-01299-7. Epub 2023 Feb 16. Drug Deliv Transl Res. 2023. PMID: 36795198 Review.
Breast cancer (BC) is the most frequently diagnosed malignancy in women worldwide. Almost 70-80% of cases of BC are curable at the early non-metastatic stage. BC is a heterogeneous disease with different molecular subtypes. Around 70% of breast tumors exhibit …
Breast cancer (BC) is the most frequently diagnosed malignancy in women worldwide. Almost 70-80% of cases of BC are curable at …
Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists.
Fusco N, Ragazzi M, Sajjadi E, Venetis K, Piciotti R, Morganti S, Santandrea G, Fanelli GN, Despini L, Invernizzi M, Cerbelli B, Scatena C, Criscitiello C. Fusco N, et al. Histol Histopathol. 2021 Dec;36(12):1235-1245. doi: 10.14670/HH-18-376. Epub 2021 Sep 29. Histol Histopathol. 2021. PMID: 34585734 Free article. Review.
Estrogen receptor (ER) status assessment by immunohistochemistry (IHC) is the gold standard test for the identification of patients with breast cancer who may benefit from endocrine therapy (ET). ...These tumors are generally classified within the lumi …
Estrogen receptor (ER) status assessment by immunohistochemistry (IHC) is the gold standard test for the identification of pat …
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression.
Basile D, Cinausero M, Iacono D, Pelizzari G, Bonotto M, Vitale MG, Gerratana L, Puglisi F. Basile D, et al. Cancer Treat Rev. 2017 Dec;61:15-22. doi: 10.1016/j.ctrv.2017.09.006. Epub 2017 Oct 6. Cancer Treat Rev. 2017. PMID: 29078133 Review.
In recent years, new therapeutic approaches have reshaped the overall strategy of breast cancer (BC) treatment and have markedly improved patient survival. This is, in part, due to novel therapies for estrogen receptor (ER)-positive BC. ...Inter …
In recent years, new therapeutic approaches have reshaped the overall strategy of breast cancer (BC) treatment and have marked …
Overview of the relevance of PI3K pathway in HR-positive breast cancer.
Vasan N, Toska E, Scaltriti M. Vasan N, et al. Ann Oncol. 2019 Dec 1;30(Suppl_10):x3-x11. doi: 10.1093/annonc/mdz281. Ann Oncol. 2019. PMID: 31859348 Free PMC article. Review.
One of the hallmarks of hormone receptor (HR)-positive breast cancer is its dependence on the phosphatidylinositol-3-kinase (PI3K) pathway. Here, we review the epidemiologic, functional, and pharmacologic interactions between oncogenic PI3K and the …
One of the hallmarks of hormone receptor (HR)-positive breast cancer is its dependence on the phosphatidylinosit …
24,439 results
You have reached the last available page of results. Please see the User Guide for more information.